Gilead Sciences to acquire Repare’s RP-3467
Gilead will pay Repare $25m upfront, and up to an additional $5m upon completion of certain technology transfer activities.
Drug Development
Zydus and Bioeq partner for commercialisation of Nufymco in US
Genentech secures FDA approval for Lunsumio VELO SC for follicular lymphoma
Samsung Biologics to acquire Human Genome Sciences
Cytokinetics receives FDA approval for MYQORZO tablets for oHCM
J&J receives FDA approval for lung cancer therapy
EC approves Incyte’s Minjuvi combo for follicular lymphoma
Alnylam plans $250m investment in Norton manufacturing facility, US
